Human TAFA2/FAM19A2 Alexa Fluor® 350-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # AF4179U
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Ala31-His131
Accession # Q8N3H0
Specificity
Clonality
Host
Isotype
Applications for Human TAFA2/FAM19A2 Alexa Fluor® 350-conjugated Antibody
Immunohistochemistry
Neutralization
Formulation, Preparation, and Storage
Purification
Formulation
Shipping
Stability & Storage
Background: TAFA2/FAM19A2
TAFA2 (also FAM19A2) is a secreted, 11 kDa member of the FAM19/TAFA family of chemokine-like proteins (1). It is synthesized as a 131 amino acid (aa) precursor that contains a 30 aa signal sequence and a 101 aa mature chain. Like other members of the FAM19/TAFA family, with the exception of TAFA5, mature TAFA1 contains 10 regularly spaced cysteine residues that follow the pattern CX7CCX13CXCX14CX11CX4CX5CX10C, where C represents a conserved cysteine residue and X represents any noncysteine amino acid (1). Human TAFA2 is 97% aa identical to mouse TAFA2 (1). TAFA2 expression can be detected in the central nervous system (CNS), colon, heart, lung, spleen, kidney, and thymus, but its expression in the CNS is 50- to 1000-fold higher than in other tissues (1). Within the CNS, TAFA2 expression is highest in the occipital and frontal cortex (3- to 10-fold more abundantly expressed than in other cortical regions) and medulla (1). The biological functions of TAFA family members remain to be determined, but there are a few tentative hypotheses. First, TAFAs may modulate immune responses in the CNS by functioning as brain-specific chemokines, and may act with other chemokines to optimize the recruitment and activity of immune cells in the CNS (1). Second, TAFAs may represent a novel class of neurokines that act as regulators of immune nervous cells (1 - 2). Finally, TAFAs may control axonal sprouting following brain injury (1).
Long Name
Alternate Names
Gene Symbol
UniProt
Additional TAFA2/FAM19A2 Products
Product Specific Notices for Human TAFA2/FAM19A2 Alexa Fluor® 350-conjugated Antibody
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
For research use only